What is TriNetX?
Founded in 2013, TriNetX operates as a global health research network dedicated to optimizing clinical research and enabling scientific discoveries through the generation of real-world evidence. The company leverages real-time access to longitudinal clinical data, combined with advanced analytics, to empower researchers to address complex questions with unprecedented speed. TriNetX's platform is designed to facilitate collaboration and data-driven insights within the healthcare and pharmaceutical industries, positioning it as a critical infrastructure provider for modern medical research.
How much funding has TriNetX raised?
TriNetX has raised a total of $53M across 2 funding rounds:
Series A
$13M
Series D
$40M
Series A (2014): $13M with participation from Mitsui & Co, ITOCHU, Deerfield, and MPM Capital
Series D (2019): $40M, investors not publicly disclosed
Key Investors in TriNetX
Mitsui & Co
Mitsui & Co. is a major Japanese conglomerate with diverse business interests, likely providing strategic and financial backing to TriNetX's global health research initiatives.
ITOCHU
ITOCHU Corporation, another prominent Japanese trading company, likely contributes significant capital and potentially synergistic business development opportunities to TriNetX.
Deerfield
Deerfield Management is a healthcare-focused investment firm, suggesting a strategic interest in TriNetX's role in advancing medical research and evidence generation.
What's next for TriNetX?
With its substantial enterprise-level backing, TriNetX is poised for accelerated expansion and innovation. The company's strategic focus will likely involve further enhancing its data analytics capabilities, broadening its network of healthcare providers and researchers, and potentially exploring new therapeutic areas for real-world evidence application. This significant capital infusion signals a commitment to scaling operations and solidifying its market leadership in the rapidly evolving field of health data analytics and clinical research optimization. The company's trajectory suggests a continued emphasis on leveraging its unique data assets to drive impactful medical advancements.
See full TriNetX company page
